RetinalGeniX™ Technologies Inc. Announces the Submission of Two Provisional Patent Applications For Investigational Therapeutic Drugs
PETALUMA, Calif., Nov. 9, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), today announced that it has submitted two provisional patent applications to the US Patent Office for its investigational therapeutic drug candidates RTG-2023 and RTG-2024. [Click here for full press release]
RetinalGeniX Contracts With Avania CRO to Provide Guidance for Interactions With FDA on Development of Two Drug Therapies and the RetinalCam™ Image Visualization Device
PETALUMA, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), today announced that it has contracted with Avania CRO to provide guidance for the Company’s interactions with the FDA for the development of [1] RTG-2023 for the treatment of dry age-related macular degeneration (dry AMD) and [2] RTG-2024 for the treatment of Alzheimer’s syndrome dementia, and [3] the RetinalCam™ image visualization device. [Click here for full press release]
RetinalGeniX Technologies Inc. Focuses on Prevention of Blindness and Early Detection of Multiple Systemic Diseases
PETALUMA, Calif., Sept. 18, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX Technologies Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”) released to the public via OTC Markets, a video webinar regarding the retinal screening medical device technology being developed by the Company to help prevent blindness and multiple systemic diseases, the Company’s business opportunities and the professional background of the Company’s management team. [Click here for full press release]
RetinalGeniX IRB Approved to Conduct Study to Personalize Medical Evaluations for Patients Receiving Treatment for Wet Macular Degeneration
PETALUMA, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), today announced the launch of an Institutional Review Board (“IRB”) for research on its DNA/GPS program. The study aims to offer recommendations for enhancing the preselection process and management of ocular injections. [Click here for full press release]
RetinalGenix Technologies Inc. Announces the Addition of Fred Chasalow, Ph.D., to the Medical Advisory Board of DNA-GPS
PETALUMA, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”) today announced the addition of Fred Chasalow, Ph.D., to the Medical Advisory Board of DNA-GPS™. [Click here for full press release]
RetinalGeniX Technologies Inc. Granted Patent for Patient Home Monitoring and Physician Alert System for Ocular Anatomy
PETALUMA, Calif., July 28, 2023 (GLOBE NEWSWIRE) -- Technology Enables Physicians to Remotely Make Pre-Diagnostic Assessment Regarding Whether an In-Person Diagnostic Examination of Ocular Anatomy is Warranted. RetinalGeniX™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), this week was granted a patent for its Patient Home Monitoring and Integrated Physician Alert System For Ocular Anatomy. [Click here for full press release]
Retinalgenix Technologies, Inc. Expands Team to Hasten the Launch of DNA/GPS
PETALUMA, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), announced today the hiring of Owen Watson, MS. Watson Hired to Accelerate DNA-Based "GPS" Genetic Testing App, Which Combines with RTGN's High-Resolution Retinal Imaging Technologies Seeking to Revolutionize Diagnosis of Systemic Diseases [Click here for full press release]
RetinalGeniX™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), today previewed the completion of an Institutional Review Board (“IRB”) for research on its DNA/GPS program
PETALUMA, Calif., June 26, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), today previewed the completion of an Institutional Review Board (“IRB”) for research on its DNA/GPS program. The study aims to offer recommendations for enhancing the management of ocular injections, which have become a significant healthcare burden due to their associated complications in treating macular degeneration-related vision loss. [Click here for full press release]
RetinalGeniX™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), Announced the Acquisition of DNA-Based "GPS" Genetic Testing Combines with RTGN's High Resolution Retinal Imaging Technologies
PETALUMA, Calif., July 06, 2022 -- Acquisition of DNA-Based "GPS" Genetic Testing Combines with RTGN's High Resolution Retinal Imaging Technologies Seeks to Revolutionize Diagnosis of Systemic Diseases [click here for full press release]
RetinalGeniX™ Technologies Announces RetinalCam™ a Home Monitoring & Physician Alert System
PETALUMA, Calif., October 27, 2020 -- The First In-Home Self-Monitoring Physician Visual Alert Device with Real-Time Imaging of the Central Retina Including Streaming Video to the Physician! [click here for full press release]
RetinalGeniX™ Technologies Selects OPTIONTRAX for Equity Management
PETALUMA, Calif., Oct. 21, 2020 /PRNewswire/ -- RetinalGeniX™ Technologies, Inc. https://retinalgenix.com/ announced today that it has awarded a contract to Plan Management Corporation (PMC) for use of their OPTIONTRAX Equity Plan and Cap Table Software. RetinalGeniX™ Technologies is a private California-based medical technology company focused on prevention of blindness through mass medical retinal screening and patient home monitoring. [click here for full press release]
ADM Tronics to Develop Patented, Next-Generation Ophthalmic Diagnostic System for RetinalGeniX Technologies, Inc.
Northvale, NJ, Jan. 13, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- ADM Tronics Unlimited, Inc. (OTCQB: ADMT) announced that RetinalGeniX Technologies, Inc. (“RTI”), has entered into an engineering development agreement for ADMT to develop and manufacture RTI’s patented, next-generation ophthalmic diagnostic technology known as the RetinalGeniX™ system. [click here for full press release]
RetinalgeniX Technologies Inc. Plans to Treat Blindness Due to Diabetic Maculopathy
Petaluma, CA, Dec. 20, 2019 -- RetinalgeniX™ Technologies Inc. announced today its plans to spearhead an effective technology to aid in the treatment of blindness due to Diabetic Maculopathy worldwide. [click here for full press release]